Cancer Innovations and Breakthroughs

Abstract

The 21st century has ushered in a new era of cancer care, marked by unprecedented breakthroughs in targeted therapeutics and diagnostic technologies. From the revolution of immunotherapy to the advent of non-invasive liquid biopsies and the transformative potential of artificial intelligence (AI), these innovations promise to fundamentally reshape the global oncology landscape. However, the benefits of this progress are not equitably distributed. The African continent, in particular, faces a rapidly escalating cancer burden, with cases and deaths projected to rise by 150% by 2050.¹ This crisis is compounded by systemic barriers, including severe financial constraints, a critical shortage of specialized healthcare personnel, and underdeveloped infrastructure, which collectively contribute to the high prevalence of late-stage diagnoses. This paper critically examines the most promising global cancer innovations, contextualizing their applicability and accessibility within the unique epidemiological and socioeconomic realities of Africa. It argues that a strategic and adapted approach, emphasizing non-invasive, cost-effective, and scalable technologies, is essential for bridging the global-African care divide. By highlighting successful, collaborative initiatives and locally driven research, this analysis proposes a policy-relevant framework for a future where high-quality, equitable cancer care is not merely an aspirational goal but a tangible reality across Africa.

---

Introduction

Cancer stands as a formidable public health challenge in the 21st century, placing a staggering burden on countries and communities worldwide. In 2022 alone, an estimated 20 million new cancer cases were diagnosed, leading to nearly 10 million deaths globally.² The trajectory of this disease is alarming, with global cancer diagnoses anticipated to surge to 35 million by 2025, representing a 76.6% increase from the 2022 figures, and cancer-related fatalities projected to reach 18.5 million by 2050.²

While this global crisis is pervasive, its impact is disproportionately felt across the African continent. In sub-Saharan Africa (SSA), cancer has rapidly emerged as a major public health problem, ranking among the top three causes of premature death in nearly all countries in the region.¹ The estimated number of new cancer cases and deaths in SSA is expected to rise by approximately 150% by 2050, a surge driven by factors such as a growing and aging population, rapid urbanization, and a shift in lifestyle and risk factors.¹ This burgeoning crisis is set against a backdrop of under-resourced health systems, with the continent possessing only 3% of the world’s healthcare workers despite bearing 24% of the global disease burden.¹

Concurrently, the field of oncology is undergoing a profound transformation. Breakthroughs in therapeutic modalities, such as immunotherapy and targeted drug platforms, are redefining treatment outcomes and offering hope for previously incurable diseases.³ Similarly, diagnostic and screening capabilities are being revolutionized by advancements in liquid biopsy technologies and the application of artificial intelligence (AI).⁴ These innovations hold immense promise for enhancing treatment precision and efficacy.

This report is designed to provide a comprehensive analysis of these emerging technologies, moving beyond a simple overview to critically examine their potential and challenges within the African context. The central purpose is to explore how these advanced diagnostic and therapeutic innovations can be strategically and equitably implemented to address Africa’s burgeoning cancer crisis. By synthesizing global advancements with the unique realities on the ground, this paper seeks to offer a nuanced perspective on the future of cancer care, proposing a strategic framework that can catalyze a paradigm shift toward a more effective and just health landscape in Africa.

Section 1: The New Frontier of Cancer Therapeutics

The landscape of cancer treatment is undergoing a rapid and profound transformation, driven by a deeper understanding of cancer biology and the immune system. Emerging therapeutic modalities are moving beyond traditional chemotherapy and radiation to offer more targeted, precise, and durable responses. This section explores several of the most promising new therapeutic classes that are redefining the standards of care and shaping the future of oncology.

1.1 Immunotherapy: A Revolution in Treatment

Immunotherapy represents a groundbreaking approach that harnesses the power of the body’s own immune system to fight cancer.⁶ Unlike conventional treatments that directly attack cancer cells, immunotherapies “wake up” the immune system, training it to recognize and eliminate malignant cells.⁷ The success of these therapies in achieving complete and lasting remissions in cases previously considered incurable has established them as a new standard of care for many cancers.³

Immune Checkpoint Inhibitors (ICIs)

One of the most impactful classes of immunotherapy is Immune Checkpoint Inhibitors (ICIs). These drugs function by blocking the natural “brakes” that cancer cells use to deactivate the immune system’s T-cells.⁸ By releasing these brakes, ICIs enable T-cells to mount a sustained and effective attack against tumors.⁸ The first half of 2025 saw several significant advancements and approvals in this category. The KEYNOTE-689 trial reported that the perioperative use of pembrolizumab (

Keytruda) in patients with head and neck squamous cell carcinoma (HNSCC) resulted in a 34% lower risk of disease recurrence.⁸ Similarly, retifanlimab-dlwr (

Zynyz) was approved for patients with recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC), further expanding the clinical utility of this class of drugs.⁸

Cellular Therapies: CAR T-cells and Beyond

Adoptive cellular therapies, particularly CAR T-cell therapy, are fundamentally reshaping the treatment landscape for hematologic malignancies.⁸ This highly customized treatment involves collecting a patient’s own T-cells, genetically modifying them with a chimeric antigen receptor (CAR) to recognize and attack specific proteins on cancer cells, and then reinfusing them back into the patient.¹⁰ This process has yielded remarkable results, with clinical trials showing that CAR T-cell therapies can eliminate very advanced blood cancers and produce durable remissions, even apparent cures, in some patients with leukemia, lymphoma, and multiple myeloma.¹¹ For instance, a CAR T-cell therapy (axi-cel) was shown to eliminate cancer in nearly 80% of patients with advanced follicular lymphoma, with many remaining disease-free after three years.¹¹

Despite their success, first-generation CAR T-cells have faced challenges, particularly in the context of solid tumors and logistical hurdles related to their high-maintenance nature.¹¹ A significant innovation in 2025, however, addresses this very issue. Researchers at the University of Southern California (USC) engineered a new type of T-cell, named “EchoBack CAR T-cell,” which can be activated by a short pulse of focused ultrasound.¹⁰ This remote-controlled activation allows the cells to continuously destroy tumor cells for up to five times longer than standard CAR T-cells, potentially reducing the frequency of hospital visits from daily to once every two weeks.¹⁰ This advancement holds immense promise for resource-limited settings where frequent, long-distance travel to treatment centers is a major barrier to care. While the application of CAR T-cells to solid tumors remains a significant obstacle due to the tumor’s immunosuppressive microenvironment, ongoing research is exploring multiple next-generation approaches to overcome these limitations.¹¹

Next-Generation Vaccines

The development of cancer vaccines is also accelerating, with two distinct approaches gaining significant traction. Personalized neoantigen vaccines are designed to target unique mutations (neoantigens) present only on an individual’s tumor cells.¹³ This hyper-specific approach aims to maximize therapeutic efficacy while minimizing side effects. Early-phase clinical trials in melanoma and glioblastoma have demonstrated the ability of these vaccines to induce potent and durable immune responses.¹⁴

A more generalizable approach has emerged from the University of Florida, where an experimental mRNA vaccine was developed that successfully eliminated tumors in mice.⁷ Unlike personalized vaccines, this “universal” vaccine did not target a specific tumor protein. Instead, it was designed to simply “rev up” the immune system as if it were fighting a viral infection, making a wide range of cancer cells vulnerable to attack.⁷ This breakthrough offers the potential for an “off-the-shelf” cancer vaccine that could be broadly used across many different cancer types, providing a profound new tool in the fight against cancer.⁷

1.2 The Resurgence of Targeted Therapies

While immunotherapy dominates the headlines, other targeted therapeutic platforms are also demonstrating remarkable efficacy. These therapies leverage precise mechanisms to attack cancer cells while sparing healthy tissue, often by targeting specific proteins or pathways.

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) are a form of immunotherapy that combines the specificity of an antibody with the lethality of a chemotherapy drug.⁸ An ADC works by linking a potent cancer-killing drug to an antibody that recognizes proteins found on the surface of cancer cells.⁸ This allows the drug to be delivered directly to the tumor, where it is released to selectively destroy malignant cells, minimizing collateral damage to healthy tissues.⁸ Recent FDA approvals include

Emrelis for non-small cell lung cancer (NSCLC) and Datroway for EGFR-mutated lung cancer and certain breast cancers.⁸

Bispecific Antibodies

Bispecific antibody therapies are another innovative class of targeted drugs that have gained traction in 2025. These unique molecules are engineered to bind simultaneously to both a cancer cell and an immune cell, effectively serving as a bridge between the two.⁸ This dual-binding mechanism helps the immune system to mount a direct and precise attack on the tumor.⁸ A notable approval in this category is

Lynozyfic for the treatment of relapsed or refractory multiple myeloma.⁸

1.3 Oncolytic Viruses: Harnessing Nature’s Arsenal

Oncolytic viruses (OVs) are a promising form of cancer therapy that utilizes viruses to selectively infect and destroy cancer cells.¹⁹ These viruses, which can be naturally occurring or genetically engineered, are designed to replicate within tumor cells, leading to their destruction.²¹ As the cancer cells are destroyed, they release new virus particles that go on to infect and kill the remaining tumor.²⁰ This process, known as oncolysis, also releases tumor antigens, stimulating a host anti-tumor immune response and turning the tumor into a vaccine factory.¹⁹

The first oncolytic virus immunotherapy, T-VEC (Imlygic), a modified herpes virus, was approved by the U.S. Food and Drug Administration (FDA) for melanoma in 2015.¹⁹ The phase III trial for T-VEC demonstrated that local injections not only suppressed the growth of the injected tumors but also had a systemic effect that prolonged overall survival.²² Ongoing clinical trials are exploring the use of other viruses, such as the herpesvirus G47∆ for glioblastoma, with promising results.²¹

The following table provides a summary of the key emerging immunotherapies and other therapeutic modalities discussed in this section.

Therapy Type	Mechanism of Action	Key Examples & Approvals
Immune Checkpoint Inhibitors (ICIs)	Block proteins that act as “brakes” on the immune system, allowing T-cells to attack cancer cells.8	Pembrolizumab (for HNSCC, melanoma, etc.), Retifanlimab-dlwr (for SCAC).8
CAR T-cell Therapy	Genetically engineer a patient’s own T-cells to express a CAR that targets and kills cancer cells.10	Tisagenlecleucel (Kymriah), Axi-cel (Yescarta). Approved for blood cancers.11
Next-Gen Vaccines	Induce an immune response against tumors either universally (mRNA vaccines) or by targeting unique mutations (neoantigen vaccines).7	UF’s experimental mRNA vaccine (in mice), NeoVax (in clinical trials).7
Antibody-Drug Conjugates (ADCs)	Link a potent drug to an antibody that targets cancer-associated proteins, delivering the drug directly to the tumor.8	Datroway (for NSCLC and breast cancer), Emrelis (for NSCLC), Enhertu (for breast cancer).8
Bispecific Antibodies	Molecules that bind to both a cancer cell and an immune cell, facilitating a direct immune attack on the tumor.8	Lynozyfic (for multiple myeloma).8
Oncolytic Viruses (OVs)	Viruses that selectively infect and destroy cancer cells while also stimulating an anti-tumor immune response.19	T-VEC (for melanoma), G47∆ (in clinical trials for glioblastoma).19

Section 2: Transforming Diagnostics and Screening

The ability to detect and accurately characterize cancer is a cornerstone of effective treatment. The rapid evolution of diagnostic technologies, particularly in the areas of liquid biopsies and artificial intelligence, is creating unprecedented opportunities for earlier detection and more personalized care. This is especially significant in contexts where traditional diagnostic infrastructure is lacking.

2.1 Liquid Biopsies: A Non-Invasive Window into Cancer

A liquid biopsy is a revolutionary, minimally invasive diagnostic approach that examines circulating tumor components in bodily fluids, most commonly blood.⁴ As tumors grow, they shed bits of their genetic material and even whole cells into the bloodstream. A liquid biopsy detects these circulating tumor DNA (ctDNA) fragments and circulating tumor cells (CTCs), providing a “non-invasive window into the tissue” of interest.²⁴

This technology offers a multitude of clinical applications, including early cancer detection and screening, molecular profiling for targeted treatment selection, and real-time monitoring of a tumor’s response to therapy.²⁵ For patients already diagnosed with cancer, a liquid biopsy can provide dynamic information about the disease by tracking genetic changes over time, helping oncologists to assess treatment effectiveness or detect relapse before it becomes clinically apparent.⁴ Several tests have already received FDA approval for specific uses, such as

Guardant360 CDx and FoundationOne Liquid CDx, which detect genetic errors to help guide treatment decisions, and Cell Search CTC, which is used to predict the likely prognosis for people with metastatic breast, prostate, or colon cancer.²³

The promise of liquid biopsy is particularly profound for Africa and other resource-limited settings.²⁸ The continent’s cancer crisis is exacerbated by a lack of diagnostic facilities and a severe shortage of pathologists, leading to delayed or inaccurate diagnoses.³⁰ Traditional tissue biopsies are invasive, painful, and often fail to capture the genomic heterogeneity of a tumor, a significant problem given the high tumor heterogeneity observed in African populations.²⁸ A liquid biopsy, by contrast, is a simple blood draw, making it easily repeatable and more acceptable to patients.⁴ Because it can provide a comprehensive overview of a tumor’s molecular profile from a single sample, it can overcome the challenge of spatial heterogeneity without the need for multiple surgical procedures.²⁵

The implementation of this technology is already underway on the continent. In a monumental step forward, Nigeria-based Syndicate Bio became the first lab in Africa to implement the MSK-ACCESS assay, a highly validated ctDNA test.³² This initiative makes cutting-edge liquid biopsy testing widely available to patients across the continent, addressing the historical need for patients to travel out of Africa for such diagnostics.³² The AI-REAL clinical trial in East Africa is also specifically evaluating the clinical utility and health-economic benefits of liquid biopsy compared to traditional histopathology for diagnosing aggressive lymphomas in children, providing a crucial proof-of-principle for its use in low-resource contexts.³³

Characteristic	Traditional Tissue Biopsy	Liquid Biopsy (e.g., ctDNA analysis)
Invasiveness	Invasive, often requiring a surgical procedure 26	Minimally invasive, typically a simple blood draw 23
Procedural Cost	High, requires specialized equipment and personnel 29	Lower, simpler procedure 29
Real-time Monitoring	Difficult and risky to repeat frequently 26	Easily repeatable, providing dynamic, real-time information 4
Tumor Heterogeneity	May not capture the full genomic profile of the tumor due to sampling limitations 4	Provides a comprehensive overview of the complete molecular profile, overcoming spatial heterogeneity 25
Patient Experience	Painful, carries risks of complications 26	Minimal discomfort, similar to a standard blood test 23

2.2 The Role of Artificial Intelligence in Precision Diagnostics

Artificial intelligence (AI) is revolutionizing the field of cancer diagnosis by enhancing the speed, accuracy, and consistency of detecting malignancies.⁵ By processing vast volumes of medical images, pathology slides, genomic sequences, and electronic health records, AI can identify subtle patterns that are often imperceptible to the human eye.⁵

In medical imaging, AI algorithms have demonstrated accuracy on par with or exceeding expert radiologists in screening for breast and lung cancers on mammograms and CT scans.⁵ These systems can identify subtle lesions, reduce false-negative rates, and help standardize interpretations across different institutions.⁵ AI is also being used in pathology to scan digital slides and distinguish benign from malignant changes, aiding in the detection of micrometastases and rare cancer subtypes.⁵

Beyond diagnostics, AI is also playing a crucial role in improving the efficiency of cancer research. At the American Society of Clinical Oncology (ASCO) annual meeting, the growing impact of AI in streamlining clinical trial recruitment and data analysis was highlighted.⁸ AI platforms can simplify time-consuming tasks like patient screening and matching, a significant barrier to research globally and particularly in Africa.⁸ For example, the City of Hope’s HopeLLM platform assists physicians in summarizing patient histories and identifying trial matches.⁸

The application of AI in Africa is not merely a theoretical concept but a developing reality. African scientists and innovators are leveraging AI to address specific local challenges and compensate for existing infrastructure and workforce gaps. In Uganda, the PapsAI platform uses AI to automate the analysis of pap smear screenings, making early cervical cancer diagnosis more affordable and accurate, which is critically important given that cervical cancer is the leading cause of cancer death in SSA.¹ Similarly, Ethiopia has initiated a pioneering AI project for early cancer detection, which includes an advanced breast cancer detection module currently in its trial phase.³⁸ These initiatives demonstrate a strategic recognition that by focusing on non-invasive, cost-effective, and scalable technologies like AI, the continent can make significant strides in public health despite its resource limitations.³⁹

Section 3: Contextual Factors and Alternative Approaches

While the development of new treatments and diagnostic tools is central to the future of oncology, a holistic understanding of cancer also requires an examination of environmental factors, natural biological phenomena, and adjunct therapies. This section explores several of these contextual elements, providing a broader perspective on the ongoing fight against cancer.

3.1 Environmental Carcinogenesis: The Growing Threat of Microplastics in Africa

The presence of microplastics in the environment is an escalating global concern, and emerging research suggests a potential link to human health issues, including cancer.⁴¹ Microplastics are tiny particles, less than 5 millimeters in size, that shed from plastic as it degrades.⁴² They are now pervasive in human tissues, having been detected in blood, lungs, liver, and even the placenta.⁴¹

The study of microplastics and their health effects is in its early stages, but preclinical studies on human cells and animals have raised significant red flags. Proposed mechanisms by which microplastics may contribute to cancer risk include causing chronic inflammation, oxidative stress, DNA damage, and hormone disruption.⁴¹ They may also act as carriers for other toxic pollutants, such as heavy metals, that can leach into the body.⁴¹

The concern surrounding microplastics takes on a unique urgency in Africa, where rapid urbanization, high plastic consumption, and limited waste management infrastructure are prevalent.⁴⁵ Countries like South Africa and Nigeria face particularly high levels of contamination, with over 80% of South African freshwater sources containing microplastic pollution.⁴⁵ The Nile and Niger rivers, for example, are ranked among the top ten rivers globally for the amount of plastic debris they carry into the oceans.⁴⁶ These factors suggest that African populations may face disproportionate exposure to microplastics, underscoring the need for more localized research and policy interventions.

3.2 Spontaneous Regression: Insights from the Body’s Natural Defenses

Spontaneous regression, a rare and perplexing phenomenon in which a malignancy partially or completely disappears without therapeutic intervention, has long intrigued the medical community.⁴⁸ This occurrence has been documented in almost all types of cancer, though it is most frequently reported in cases of neuroblastoma, renal cell carcinoma, and malignant melanoma.⁴⁸ While its frequency is estimated to be as low as 1 in every 60,000 to 100,000 cancer cases, the phenomenon provides a profound testament to the body’s natural defenses.⁴⁸

The precise mechanisms behind spontaneous regression are not fully understood, but a leading hypothesis posits that it is caused by a sudden, powerful activation of the immune system.⁴⁸ Other proposed factors include hormonal mediation, induction of differentiation, tumor necrosis, and inhibition of angiogenesis.⁵⁰ This phenomenon serves as a real-world demonstration of the immune system’s immense anti-tumor potential. Understanding how and why the body’s defenses are sometimes able to spontaneously cure cancer offers invaluable clues for the development of new and more effective immunotherapies. By studying the biological and molecular events that lead to spontaneous remission, researchers can uncover new pathways to intentionally provoke a similar anti-cancer response in patients.

3.3 The Role of Fasting in Cancer Prevention and Treatment

The practice of fasting has gained attention in the oncology community as a potential adjunct to conventional cancer treatments. The central theory is that fasting triggers a metabolic shift that may inhibit cancer cell proliferation by depriving them of glucose and other essential nutrients.⁵² This concept is supported by the “Warburg effect,” which describes how cancer cells preferentially rely on glycolysis for energy.⁵² Furthermore, proponents of fasting suggest that it induces a state of “differential stress resistance” (DSR), which protects normal cells from the toxic side effects of chemotherapy while making cancer cells more vulnerable.⁵³

While these hypotheses are compelling, the scientific evidence from large-scale human trials remains limited.⁵² Preclinical and small-scale human studies have shown some promising results. A randomized trial on breast cancer patients found that a fasting-mimicking diet was well-tolerated and appeared to reduce the toxicity of chemotherapy, leading to significantly higher neutrophil and erythrocyte counts.⁵³ However, no human study has yet proven that fasting alone can directly kill cancer cells or replace conventional treatment.⁵⁴ The practice carries significant risks, including malnutrition, muscle wasting, and a weakened immune system, which could worsen a patient’s prognosis.⁵² Leading organizations, such as the American Cancer Society, caution against using fasting as a primary treatment and recommend that it only be explored in a supervised clinical setting.⁵⁴

3.4 Breast Implant-Associated Lymphoma (BIA-ALCL)

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare and distinct type of cancer of the immune system, not breast cancer itself, that has been linked to textured breast implants.⁵⁵ This condition develops in the fluid or scar tissue surrounding the implant, typically years after implantation.⁵⁷ The risk of developing BIA-ALCL is considered low, with current estimates ranging from 1 in 2,207 to 1 in 86,029 for women with textured implants, and it has not been associated with smooth implants.⁵⁶

The most common symptoms include persistent breast swelling or enlargement, pain, or the presence of a mass or lump in the breast or armpit.⁵⁵ Diagnosis typically begins with an ultrasound, which can detect fluid accumulation or lumps.⁵⁵ If a fluid collection is found, a needle biopsy is performed, and the fluid is tested for specific biomarkers, such as CD30, to confirm the diagnosis.⁵⁶

For the majority of patients, BIA-ALCL is curable, especially when detected early.⁵⁵ The primary treatment is complete surgical removal of the implant and the surrounding fibrous capsule.⁵⁵ For patients with early-stage disease confined to the capsule, this procedure may be the only treatment needed, and the prognosis is excellent.⁵⁵ In the rare cases where the cancer has spread, additional treatment with chemotherapy or radiation may be required.⁵⁵

Section 4: The Challenge of Implementation: Bridging the Global-African Divide

The wealth of therapeutic and diagnostic innovations described in the preceding sections highlights the incredible progress in modern oncology. However, the true measure of these advancements is not only their efficacy but also their accessibility. For Africa, a continent grappling with a complex and rapidly increasing cancer burden, the challenge lies not in a lack of innovation but in the profound systemic and socioeconomic barriers that prevent equitable access to care.

4.1 The Epidemiological Context: Understanding the African Cancer Burden

Understanding the specific nature of Africa’s cancer burden is crucial for developing relevant solutions. The most common cancer types in sub-Saharan Africa are female breast, cervical, and prostate cancers, which collectively constitute two-fifths of the cancer incidence in the region.¹ Cervical cancer, in particular, is the leading cause of cancer death in SSA, making it a critical public health priority.¹

Furthermore, a significant portion of the continent’s cancer burden is linked to infectious diseases, with infections accounting for up to 30% of cancer cases in some East African countries.¹ This differs from the cancer profiles in many high-income countries, and it underscores the need for prevention and screening strategies that are tailored to the continent’s unique epidemiological landscape.

The high prevalence of these specific cancers presents a strategic opportunity for effective intervention. Many of these cancers, such as cervical and breast cancer, are treatable and often preventable with early detection.¹ The high mortality rates on the continent are largely a result of late-stage diagnosis, where curative treatment options are no longer viable.³¹ The most impactful and pragmatic innovations for Africa may not be the most complex or expensive ones but those that directly address this diagnosis gap. For instance, non-invasive liquid biopsies and AI-powered diagnostic tools are well-suited to the context, offering scalable, affordable, and non-invasive methods to detect and monitor these high-burden cancers early.²⁸ This approach leverages technology not just for clinical advancement but for immediate public health impact.

4.2 Systemic and Socioeconomic Barriers to Equitable Care

The gap between modern cancer innovation and its implementation in Africa is a direct consequence of a multi-faceted set of systemic and socioeconomic barriers.

A primary challenge is the severe financial constraint faced by both individuals and healthcare systems.³¹ Most cancer patients in Africa must pay for treatment “out of pocket,” which is often unaffordable for a population where a significant proportion lives in extreme poverty.³⁰ This leads to high rates of treatment abandonment and contributes to increased mortality.³⁰ The lack of a strong health insurance framework further exacerbates this issue, leaving most individuals without a financial safety net for catastrophic health events.³¹

This financial challenge is compounded by a critical shortage of infrastructure and personnel. Many African countries lack sufficient diagnostic facilities, specialized oncology centers, and essential equipment, such as radiotherapy machines and pathology labs.³⁰ This forces patients to travel long distances for care, which is often logistically and financially unfeasible.³¹ The problem is further aggravated by a severe shortage of skilled oncology professionals, with some countries reportedly having fewer than one oncologist per million people.³¹ This high patient-to-oncologist ratio compromises the quality of care and leads to significant delays in diagnosis and treatment.³¹

Finally, sociocultural barriers and a general lack of public awareness contribute to a high rate of late-stage patient presentation.³¹ Many individuals may hold misconceptions about cancer, associating it with supernatural causes or viewing it as a death sentence, leading them to delay seeking medical care and instead rely on alternative therapies.³¹

The following table summarizes these key challenges and highlights some of the initiatives that are working to address them.

Challenge	Specific Issues	Corresponding Initiatives & Solutions
Financial Constraints	High out-of-pocket costs, lack of health insurance, unaffordable drugs.30	CHAI/ACS partnerships securing up to 59% savings on essential drugs; local manufacturing of medicines; pooled procurement of drugs across regions.61
Infrastructure Gaps	Shortage of oncology centers, radiotherapy machines, and diagnostic labs; poor referral systems.30	Establishment of regional centers of excellence; decentralized essential services; leveraging technology like AI to compensate for facility shortages.37
Workforce Shortages	Critical lack of oncologists and specialized staff; limited training opportunities.30	AORTIC and AC3T promoting training and capacity-building; virtual tumor boards; integrated health curriculums.36
Late Patient Presentation	Low public awareness, stigma, fatalistic cultural beliefs.31	Community-based cancer screenings; health education and promotion campaigns by healthcare professionals; leveraging technology for public outreach.30
Data Gap	Lack of comprehensive cancer registries; underrepresentation in global genomic research.2	African BioGenome Project, Prostate Cancer Transatlantic Consortium (CaPTC); AC3T online platform to publicize local capabilities.2

4.3 Collaborative Pathways and Access Initiatives

Despite the formidable barriers, a growing number of collaborative initiatives are actively working to bridge the care gap and empower African healthcare systems. A crucial aspect of this effort involves shifting the dynamic from one of dependency to one of empowerment.

Partnerships between non-governmental organizations and pharmaceutical companies have yielded significant progress in making essential cancer medicines more affordable. The Clinton Health Access Initiative (CHAI) and the American Cancer Society (ACS) have established groundbreaking agreements with companies like Pfizer and Novartis to provide 26 lifesaving cancer treatments at reduced prices in 30 countries across Africa and Asia.⁶² These collaborations have resulted in average savings of 59% for purchasers and have directly led to an increase in the volume of medications procured and new levels of access to quality therapies for patients.⁶²

Furthermore, clinical trials are increasingly recognized not just as a research tool but as a proactive route to bringing innovative therapies and functional infrastructure to the continent.⁶⁷ African patients have historically been severely underrepresented in global clinical trials, which not only limits their access to cutting-edge treatments but also creates a data gap that compromises the development of therapies tailored to their unique genomic diversity.²

However, this dynamic is changing. Organizations such as the African Consortium for Cancer Clinical Trials (AC3T) and the African Organisation for Research & Training in Cancer (AORTIC) are working to build local clinical trial capacity and foster African investigator-initiated research.³⁶ The AC3T online platform, for instance, publicizes the clinical trial infrastructure and capabilities of healthcare facilities across Africa, which helps to attract global partners and catalyzes a movement toward a more equitable research landscape.³⁶ This shift transforms Africa from a passive recipient of global health aid to an active and self-sufficient hub for cancer research and innovation. By building local expertise and infrastructure, these initiatives are creating a sustainable pathway for innovative cancer therapies and diagnostics to become a standard of care for African populations.

Discussion and Recommendations

The synthesis of global cancer innovations with the realities of the African continent reveals a complex but manageable challenge. While the high-cost, high-tech nature of many modern therapies, such as CAR T-cell therapy, presents significant implementation barriers in Africa, other innovations, particularly in the realm of diagnostics, are a perfect fit for the continent’s needs. The non-invasive, repeatable, and scalable nature of liquid biopsies and AI-powered diagnostic tools directly addresses the most critical barriers to care in Africa: late-stage diagnosis due to a lack of infrastructure and a shortage of specialized personnel.²⁸ These technologies can be strategically deployed to have the greatest public health impact by enabling early detection of the most prevalent and treatable cancers, such as cervical and breast cancer.¹

To effectively bridge the global-African care divide, a multi-pronged approach is essential. The following recommendations are proposed for policymakers, healthcare leaders, and global partners:

1. Prioritize Foundational Investments in Health Systems: Governments must increase budget allocation for healthcare and research, viewing health costs as a critical long-term investment rather than a short-term expenditure.³⁹ This investment should focus on building robust digital health infrastructure, improving data collection, and establishing comprehensive cancer registries.³⁰
2. Foster Public-Private Partnerships for Equitable Access: Governments, NGOs, and pharmaceutical companies should expand on successful models like the CHAI/ACS Cancer Access Partnership to negotiate affordable access to a broader range of essential medicines and diagnostic technologies.⁶² This will ensure that quality-assured products are available at prices that are sustainable for African health systems and affordable for patients.
3. Expand and Localize Clinical Research: Global sponsors must commit to including more African sites and a more diverse patient population in clinical trials.⁶⁸ This is not only a matter of equity but a scientific imperative, as Africa’s vast genomic diversity can provide invaluable insights for global cancer research that are currently being overlooked.² Simultaneously, funding and support for African-led research consortia, such as AC3T and AORTIC, must be increased to empower local investigators and build indigenous capacity.
4. Strategically Deploy Scalable Technology: A focus on implementing non-invasive, high-impact innovations like AI and liquid biopsies is critical. By supporting initiatives like Uganda’s PapsAI platform and the AI-REAL trial, stakeholders can demonstrate the feasibility and cost-effectiveness of these technologies, which can then be scaled to address national and regional health priorities.³³
5. Address Environmental Carcinogens and Health Literacy: Given the potential link between environmental factors and the rising cancer burden, policy action is required to address plastic pollution and improve waste management infrastructure.⁴⁵ This must be combined with a concerted effort to enhance public health education, raise cancer awareness, and counter socio-cultural barriers that lead to delayed diagnosis.³¹

Conclusion

The convergence of groundbreaking cancer innovations and a burgeoning cancer crisis in Africa presents a pivotal moment in global health. While the systemic challenges are formidable—from financial hardship and infrastructure deficits to critical workforce shortages and a high prevalence of late-stage diagnoses—a clear pathway to a more equitable future is emerging. This pathway is defined not by the passive adoption of Western solutions but by the strategic adaptation and localization of technologies that are non-invasive, cost-effective, and scalable. By leveraging the power of collaboration between governments, NGOs, and the private sector, and by empowering local researchers to lead and innovate, Africa can transform its position from a recipient of aid to a central hub of progress. The continued commitment to expanding clinical trials, securing affordable access to life-saving medicines, and deploying targeted technologies like liquid biopsies and AI offers a profound opportunity to fundamentally change the trajectory of cancer on the continent, bringing the promise of a new era of cancer care to all.

Works cited

1. Cancer in Sub-Saharan Africa, accessed August 26, 2025, https://canceratlas.cancer.org/burden-of-cancer/cancer-in-sub-saharan-africa/
2. Current landscape of cancer genomics research in sub-Saharan Africa – a review of literature – Frontiers, accessed August 26, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1512005/pdf
3. Cancer Clinical Trials, accessed August 26, 2025, https://www.cancerresearch.org/cancer-clinical-trials
4. Liquid Biopsy: A Breakthrough Technology in Early Cancer Screening, accessed August 26, 2025, https://www.xiahepublishing.com/2835-3315/CSP-2024-00031
5. How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening – OncoDaily, accessed August 26, 2025, https://oncodaily.com/oncolibrary/artificial-intelligence-ai
6. Immunotherapy Clinical Trials – Moffitt Cancer Center, accessed August 26, 2025, https://www.moffitt.org/treatments/immunotherapy/clinical-trials/
7. Cure for cancer? New mRNA cancer vaccine wipes out tumors in mice, raises hopes for universal treatment, accessed August 26, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/cure-for-cancer-new-mrna-cancer-vaccine-wipes-out-tumors-in-mice-raises-hopes-for-universal-treatment/articleshow/123443854.cms
8. Top Oncology Innovations That Shaped the First Half of 2025 | Cancer News – Binaytara, accessed August 26, 2025, https://binaytara.org/cancernews/article/top-oncology-innovations-that-shaped-the-first-half-of-2025
9. FDA Approvals in Oncology: April-June 2025 | Blog | AACR, accessed August 26, 2025, https://www.aacr.org/blog/2025/07/01/fda-approvals-in-oncology-april-june-2025/
10. New “Smart” Immune Cells: A Breakthrough for Long-Lasting Tumor Destruction, accessed August 26, 2025, https://viterbischool.usc.edu/news/2025/04/new-smart-immune-cells-a-breakthrough-for-long-lasting-tumor-destruction/
11. CAR T Cells: Engineering Immune Cells to Treat Cancer – NCI, accessed August 26, 2025, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
12. Top cancer research stories of 2024, accessed August 26, 2025, https://cancerblog.mayoclinic.org/2024/12/30/top-cancer-research-stories-of-2024/
13. Advancements and challenges in personalized neoantigen-based cancer vaccines – PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11949952/
14. Updated NeoVax cancer vaccine shows improved immune response in melanoma trial, accessed August 26, 2025, https://www.news-medical.net/news/20250710/Updated-NeoVax-cancer-vaccine-shows-improved-immune-response-in-melanoma-trial.aspx
15. Neoantigen vaccines: advancing personalized cancer immunotherapy, accessed August 26, 2025, https://www.explorationpub.com/Journals/ei/Article/1003190
16. Surprising finding could pave way for universal cancer vaccine – UF Health, accessed August 26, 2025, https://ufhealth.org/news/2025/surprising-finding-could-pave-way-for-universal-cancer-vaccine
17. Transforming Cancer Therapy: Insights from 2025 H1 FDA Approvals and Preclinical Drug Discovery – Crown Bioscience Blog, accessed August 26, 2025, https://blog.crownbio.com/transforming-cancer-therapy-insights-from-2025-h1-fda-approvals-and-preclinical-drug-discovery
18. Oncology (Cancer)/Hematologic Malignancies Approval Notifications – FDA, accessed August 26, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
19. Oncolytic Virus Therapy – Cancer Research Institute, accessed August 26, 2025, https://www.cancerresearch.org/immunotherapy-by-treatment-types/oncolytic-virus-therapy
20. Oncolytic virus – Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Oncolytic_virus
21. Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10368374/
22. Oncolytic virus therapy: A new era of cancer treatment at dawn – PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5084676/
23. Liquid Biopsy: What It Is & Procedure Details – Cleveland Clinic, accessed August 26, 2025, https://my.clevelandclinic.org/health/diagnostics/23992-liquid-biopsy
24. The future of liquid biopsy | Stanford University School of Engineering, accessed August 26, 2025, https://engineering.stanford.edu/news/future-liquid-biopsy
25. Circulating tumour DNA for cancer patients — Knowledge Hub, accessed August 26, 2025, https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/circulating-tumour-dna-for-cancer-patients/
26. Liquid Biopsies: A Revolution in Early Cancer Detection and Monitoring, accessed August 26, 2025, https://www.aicr.org/resources/blog/liquid-biopsies-a-revolution-in-early-cancer-detection-and-monitoring/
27. Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape | JCO Precision Oncology – ASCO Publications, accessed August 26, 2025, https://ascopubs.org/doi/10.1200/PO.23.00609
28. The Prospect and Challenges to the Flow of Liquid Biopsy in Africa – PMC – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6721679/
29. Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa – MDPI, accessed August 26, 2025, https://www.mdpi.com/2073-4409/12/22/2663
30. Addressing cancer care inequities in sub-Saharan Africa: current …, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10496173/
31. Erick Mahatara: Barriers to Accessing Cancer Care and Its Fatal Outcomes in African Countries – OncoDaily, accessed August 26, 2025, https://oncodaily.com/blog/erick-mahatara260480
32. SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy …, accessed August 26, 2025, https://www.sophiagenetics.com/news/sophia-genetics-announces-syndicate-bio-as-first-liquid-biopsy-customer-in-africa/
33. A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa “(AI-REAL)” – PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/35501771/
34. AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment, accessed August 26, 2025, https://www.delveinsight.com/blog/role-of-ai-in-cancer-diagnostics
35. Power of AI/ML in Medical Imaging: Role in Cancer Diagnosis & treatment – Excelra, accessed August 26, 2025, https://www.excelra.com/whitepaper/ai-ml-medical-imaging-cancer-diagnosis-treatment/
36. African Consortium for Cancer Clinical Trials – BIO Ventures for …, accessed August 26, 2025, https://bvgh.org/african-consortium-for-cancer-clinical-trials/
37. Artificial Intelligence: A New Era in the fight against Cancer in Africa …, accessed August 26, 2025, https://afidep.org/artificial-intelligence-a-new-era-in-the-fight-against-cancer-in-africa/
38. Ethiopia Harnesses AI for Early Cancer Detection and National Development – FurtherAfrica, accessed August 26, 2025, https://furtherafrica.com/2025/06/05/ethiopia-harnesses-ai-for-early-cancer-detection-and-national-development/
39. Impact of artificial intelligence and digital technology-based diagnostic tools for communicable and non-communicable diseases in Africa – PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12242046/
40. Artificial intelligence and machine learning for early detection and diagnosis of colorectal cancer in sub-Saharan Africa – PMC – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9177787/
41. Microplastics and Cancer: Your Questions Answered, accessed August 26, 2025, https://blog.dana-farber.org/insight/2025/03/microplastics-and-cancer-what-you-need-to-know/
42. Microplastics Everywhere | Harvard Medicine Magazine, accessed August 26, 2025, https://magazine.hms.harvard.edu/articles/microplastics-everywhere
43. Microplastics and our health: What the science says – Stanford Medicine, accessed August 26, 2025, https://med.stanford.edu/news/insights/2025/01/microplastics-in-body-polluted-tiny-plastic-fragments.html
44. Microplastics: Are we facing a new health crisis – and what can be done about it?, accessed August 26, 2025, https://www.weforum.org/stories/2025/02/how-microplastics-get-into-the-food-chain/
45. Microplastics and the South African health crisis no one’s talking about – ZAWYA, accessed August 26, 2025, https://www.zawya.com/en/economy/africa/microplastics-and-the-south-african-health-crisis-no-ones-talking-about-kbrstx1e
46. The occurrence of microplastics in African ecosystems. – ResearchGate, accessed August 26, 2025, https://www.researchgate.net/figure/The-occurrence-of-microplastics-in-African-ecosystems_tbl2_363507117
47. Microplastics in Africa’s Land Ecosystems: Challenges & Collaboration, accessed August 26, 2025, https://bioengineer.org/microplastics-in-africas-land-ecosystems-challenges-collaboration/
48. (PDF) Spontaneous tumor regression – ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/304711854_Spontaneous_tumor_regression
49. Why Do Some Cancers Disappear on Their Own? – Doctors Explain, accessed August 26, 2025, https://doctorsexplain.net/why-do-some-cancers-disappear-on-their-own/
50. Spontaneous regression of cancer: possible mechanisms – PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/9891219/
51. Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review) – PMC – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3412538/
52. Fasting as Cancer Treatment: Myth or Breakthrough in Oncology – PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12035504/
53. Fasting mimicking diet during neo-adjuvant chemotherapy in breast cancer patients: a randomized controlled trial study – Frontiers, accessed August 26, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1483707/full
54. Intermittent Fasting and Cancer: What Human Studies Reveal | SHAREing & CAREing, accessed August 26, 2025, https://shareing-careing.org/intermittent-fasting-and-cancer-what-human-studies-reveal/
55. BIA-ALCL: Breast Implant-Associated Cancer, Symptoms & Treatment – Cleveland Clinic, accessed August 26, 2025, https://my.clevelandclinic.org/health/diseases/21078-bia-alcl
56. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) | ASPS, accessed August 26, 2025, https://www.plasticsurgery.org/patient-safety/breast-implant-safety/bia-alcl-summary
57. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) | FDA, accessed August 26, 2025, https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl
58. Breast implant associated cancer: consumer information, accessed August 26, 2025, https://www.tga.gov.au/products/medical-devices/breast-implant-hub/breast-implant-associated-cancer-consumer-information
59. Africa – Statistics at a glance, 2022 Top 5 most frequent cancers Number of new cases Number of deaths Number of prevalent cases (5-year), accessed August 26, 2025, https://gco.iarc.who.int/media/globocan/factsheets/populations/903-africa-fact-sheet.pdf
60. Challenges and Recommendations for Improving Cancer Research and Practice in Nigeria: A Qualitative Study With Multi-Stakeholders in Oncology Research and Practice – PMC – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11539147/
61. Where does cancer care stand in Africa today? | WHO | Regional …, accessed August 26, 2025, https://www.afro.who.int/news/where-does-cancer-care-stand-africa-today
62. New agreements to lower prices and increase access to lifesaving cancer treatment in sub-Saharan Africa, accessed August 26, 2025, https://www.clintonhealthaccess.org/news/agreements-to-increase-access-to-cancer-treatment-in-africa/
63. New Agreements to Expand Access to 20 Lifesaving Cancer Medicines for Countries in Sub-Saharan Africa and Asia – Jun 29, 2020, accessed August 26, 2025, https://pressroom.cancer.org/2020-06-29-New-Agreements-to-Expand-Access-to-20-Lifesaving-Cancer-Medicines-for-Countries-in-Sub-Saharan-Africa-and-Asia
64. AORTIC AFRICA – African Organisation for Research & Training in Cancer, accessed August 26, 2025, https://aortic-africa.org/
65. Cancer – Clinton Health Access Initiative, accessed August 26, 2025, https://www.clintonhealthaccess.org/our-programs/cancer/
66. Cancer Access Partnership (CAP) – Allied Against Cancer, accessed August 26, 2025, https://www.alliedagainstcancer.org/access-partnership
67. Cancer Clinical Trials in Africa—An Untapped Opportunity – PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8440011/
68. Improving access to innovative medicines in Africa starts with clinical trials, accessed August 26, 2025, https://www.gavi.org/vaccineswork/improving-access-innovative-medicines-africa-starts-clinical-trials